Investor Hub

Novavax, Inc. is a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases.

Latest investor presentation

Latest investor presentation

Latest clinical presentation
Latest quarterly earnings
Annual report

Annual report

Latest publications, posters & presentations

Our research

Global ticker
NASDAQNVAX
Latest press releases Events & presentation Reports & financials SEC filings Stock details & analyst coverage
NASDAQNVAX
YearTrailing 12-monthsCalendar year 2023Calendar year 2022Calendar year 2021Calendar year 2020Calendar year 2019Calendar year 2018Calendar year 2017Calendar year 2016Calendar year 2015Calendar year 2014Calendar year 2013Calendar year 2012Calendar year 2011Calendar year 2010Calendar year 2009Calendar year 2008Calendar year 2007Calendar year 2006Calendar year 2005Calendar year 2004Calendar year 2003Calendar year 2002Calendar year 2001Calendar year 2000Calendar year 1999Calendar year 1998Calendar year 1997Calendar year 1996
TypeAll filingsAnnual FilingsQuarterly FilingsCurrent FilingsRegistration StatementsSection 16Proxy & Information StatementsOther
FormDescriptionDateFormat
SC 13G/AAmendment to a previously filed SC 13GMay 10, 2023Open Amendment to a previously filed SC 13G in HTML.Open Amendment to a previously filed SC 13G in DOC file.Open Amendment to a previously filed SC 13G in PDF file.Open Amendment to a previously filed SC 13G in XLS file.
SC 13DFiling by person(s) reporting owned shares of common stock in a public company >5%Apr 27, 2023Open Filing by person(s) reporting owned shares of common stock in a public company >5% in HTML.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in DOC file.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in PDF file.Open Filing by person(s) reporting owned shares of common stock in a public company >5% in XLS file.
S-3ASRAutomatic shelf registration statement of securities of well-known seasoned issuersFeb 28, 2023Open Automatic shelf registration statement of securities of well-known seasoned issuers in HTML.Open Automatic shelf registration statement of securities of well-known seasoned issuers in DOC file.Open Automatic shelf registration statement of securities of well-known seasoned issuers in PDF file.Open Automatic shelf registration statement of securities of well-known seasoned issuers in XLS file.
SC 13G/AAmendment to a previously filed SC 13GFeb 9, 2023Open Amendment to a previously filed SC 13G in HTML.Open Amendment to a previously filed SC 13G in DOC file.Open Amendment to a previously filed SC 13G in PDF file.Open Amendment to a previously filed SC 13G in XLS file.
SC 13G/AAmendment to a previously filed SC 13GFeb 2, 2023Open Amendment to a previously filed SC 13G in HTML.Open Amendment to a previously filed SC 13G in DOC file.Open Amendment to a previously filed SC 13G in PDF file.Open Amendment to a previously filed SC 13G in XLS file.
SC 13G/AAmendment to a previously filed SC 13GFeb 1, 2023Open Amendment to a previously filed SC 13G in HTML.Open Amendment to a previously filed SC 13G in DOC file.Open Amendment to a previously filed SC 13G in PDF file.Open Amendment to a previously filed SC 13G in XLS file.
FWPFree Writing ProspectusDec 16, 2022Open Free Writing Prospectus in HTML.Open Free Writing Prospectus in DOC file.Open Free Writing Prospectus in PDF file.Open Free Writing Prospectus in XLS file.
SC 13G/AAmendment to a previously filed SC 13GDec 12, 2022Open Amendment to a previously filed SC 13G in HTML.Open Amendment to a previously filed SC 13G in DOC file.Open Amendment to a previously filed SC 13G in PDF file.Open Amendment to a previously filed SC 13G in XLS file.
Why invest with us

We are a biotechnology company that promotes improved health globally through the discovery, development and commercialization of innovative vaccines to prevent serious infectious diseases.

Learn more

For much of my four-decade career, I’ve worked with biotech companies trying to solve significant health challenges, including HIV. Novavax is uniquely positioned to help end this pandemic with our protein-based vaccine. I believe in NVX-CoV2373 so much.

I came out of retirement to join the fight.

Lisa Dunkle
Vice President, Global Medical Lead for Coronavirus Vaccine

Get notifications for investor updates

Sign up for notifications from Novavax including upcoming events, webcasts, research updates, daily stock closings, SEC filings, and more.

Go to email subscription 

Investor inquiries

Shareholders seeking information can contact investor relations at (240) 268-2022 or email us at ir@novavax.com

Novavax corporate policy prohibits any employees, other than designated spokespersons, from communicating with its investors.